nach oben

CNS Drugs

Erschienen in:

01.11.2005 | Adis Drug Profile

Rotigotine

In Parkinson’s Disease

verfasst von: Neil A. Reynolds, Keri Wellington, Stephanie E. Easthope

Erschienen in: CNS Drugs | Ausgabe 11/2005

Einloggen, um Zugang zu erhalten

Abstract

▲ Rotigotine is a nonergolinic dopamine D₃/D₂/D₁ receptor agonist delivered via a transdermal system and has been evaluated for the treatment of idiopathic Parkinson’s disease.
▲ Patients with early Parkinson’s disease receiving rotigotine monotherapy experienced significantly greater improvements in parkinsonian symptoms (as measured by Unified Parkinson’s Disease Rating Scale scores) compared to placebo in two large, well designed clinical trials. Significant beneficial effects versus placebo were observed with the 30 and 40 cm₂ rotigotine patches in both trials.
▲ Patients with advanced Parkinson’s disease receiving rotigotine as adjunctive therapy with levodopa experienced clinically significant reductions from baseline in ‘off’ time in two well designed clinical trials. In one trial, a large placebo effect was observed, therefore, there was no significant difference between placebo and active treatment (20, 40 and 60 cm²) for this primary efficacy variable, However, a recent study found a significant (p ≤ 0.003) reduction in ‘off’ time in rotigotine 40 and 60 cm² recipients versus that in the placebo group.
▲ Rotigotine was generally well tolerated in clinical trials as both monotherapy and when administered with levodopa; adverse events were generally mild or moderate in severity.

Neupro® is the proposed trade name for the rotigotine transdermal system that has been submitted to regulatory authorities. The use of trade names is for product identification purposes only and does not imply endorsement.

Samii A, Nutt JG, Ransom BR. Parkinson’s disease. Lancet 2004 May 29; 363(9423): 1783–93PubMedCrossRef

Lang AE, Obeso JA. Challenges in Parkinson’s disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurology 2004 May; 3(5): 309–16PubMedCrossRef

Chan KL, Jagait P, Tugwell C. Parkinson’s disease: current and future aspects of drug treatment. Hospital Pharmacist 2004; 11(1): 18–22

Stiasny-Kolster K, Kohnen R, Schollmayer E, et al. and The Rotigotine SP 666 Study Group. Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study. Mov Disord 2004; 19(12): 1432–8

Stiasny-Kolster K, Garcia-Borreguero D, Saletu B, et al. Rotigotine in the treatment of moderate to severe idiopathic restless legs syndrome — a double-blind placebo-controlled multi-center dose-finding study [abstract no. P1242 plus poster]. 9th Congress of the European Federation of Neurological Societies; 2005 Sep 17–20; Athens

Schwarz Pharma. Current development projects: Parkinson’s disease [online]. Available from URL: http://www.schwarzpharma.com [Accessed 2005 Oct 4]

Jenner P. A novel dopamine agonist for the transdermal treatment of Parkinson’s disease. Neurology 2005 Jul 26; 65(2 Suppl. 1): S3–5PubMedCrossRef

Calabrese VP, Lloyd KA, Brancazio P, et al. N-0923, a novel soluble dopamine D₂ agonist in the treatment of Parkinsonism. Mov Disord 1998 Sep; 13(5): 768–74PubMedCrossRef

Belluzzi JD, Domino EF, May JM, et al. N-0923, a selective dopamine D₂ receptor agonist, is efficacious in rat and monkey models of Parkinson’s disease. Mov Disord 1994 Mar; 9(2): 147–54PubMedCrossRef

10.

Tuite P, Riss J. Recent developments in the pharmacological treatment of Parkinson’s disease. Expert Opin Invest Drugs 2003 Aug; 12(8): 1335–52CrossRef

11.

Chase TN, Verhagen Metman L, Bravi D, et al. Dopamine-receptor subtype-selective agonists in the treatment of Parkinson’s disease. Clin Neuropharmacol 1995; 18Suppl. 1: S207–15CrossRef

12.

Kehr J, Scheller DKA. Continuous delivery of rotigotine leads to continuous dopamine receptor stimulation in a rat model [abstract no. P1285 plus poster]. 9th Congress of the European Federation of Neurological Societies; 2005 Sep 17–20; Athens

13.

Lebsanft HB, Scheller DKA, Heindl M, et al. Effect of continuous administration of rotigotine in a rat model of dyskinesia [abstract no. P297]. Mov Disord 2005; 20Suppl. 10: S89 plus poster presented at the 9th International Congress of Parkinson’s Disease and Movement Disorders; 2005 Mar 5–8; New Orleans (LA)

14.

Scheller DKA, Heindl M, Schmidt W. Continuous administration of rotigotine does not induce dyskinesia in a rat model of PD [abstract no. P1262 plus poster]. 9th Congress of the European Federation of Neurological Societies; 2005 Sep 17–20; Athens

15.

Scheller DK, Smith L., Breidenbach A, et al. Effect of rotigotine on locomotor activity and disability scores in MPTP-treated common marmosets following subcutaneous administration [abstract no. P396]. Mov Disord 2004; 19Suppl. 9: S145 plus poster presented at the 8th International Congress of Parkinson’s Disease and Movement Disorders; 2004 Jun 14–17; Rome

16.

Schneider JS, McLaughlin WW, Roeltgen DP. Anti-Parkinson effects of the selective dopamine D-2 agonist N-0923 in hemi-Parkinsonian monkeys [abstract no. 1002P]. Neurology 1992 Apr; 42(4 Suppl. 3): 443

17.

Scheller DK. Neuroprotection by rotigotine: investigations in MPTP-lesioned mice under continuous dopaminergic stimulation [abstract no. 250]. Ann Neurol 2004; 56Suppl. 8: S54 plus poster presented at the 129th Annual Meeting of the American Neurological Association; 2004 Oct 3–6; Toronto (ON)

18.

Stichel CC, Scheller DKA. Rotigotine prevents neurodegeneration in a mouse model of Parkinson’s disease [abstract no. P1286 plus poster]. 9th Congress of the European Federation of Neurological Societies; 2005 Sep 17–20; Athens

19.

Timmerman W, Rusk IN, Tepper P, et al. The effects of enantiomers of the dopamine agonist N-0437 on food consumption and yawning behaviour in rats. Eur J Pharmacol 1989 Dec 12; 174: 107–14PubMedCrossRef

20.

Hutton JT, Metman LV, Chase TN, et al. Transdermal dopaminergic D₂ receptor agonist therapy in Parkinson’s disease with N-0923 TDS: a double-blind, placebo-controlled study. Mov Disord 2001 May; 16: 459–63PubMedCrossRef

21.

The Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson’s disease. Arch Neurol 2003 Dec; 60(12): 1721–8CrossRef

22.

Cawello W, Braun M, Horstmann R. Pharmacokinetics of transdermal rotigotine in subjects with impaired renal function [abstract no. 102]. J Clin Pharmacol 2005; 45(9): 1091 plus poster presented at the 34th Annual Meeting of the American College of Clinical Pharmacology; 2005 Sep 11–13; Rockville (MD)

23.

Braun M, Cawello W, Poole K, et al. Steady-state pharmacokinetics of rotigotine in patients with early-stage Parkinson’s disease [abstract no. P1245 plus poster]. 9th Congress of the European Federation of Neurological Societies; 2005 Sep 17–20; Athens

24.

Hansen K, Braun M, Horstmann R. Low drug-drug interaction potential of rotigotine [abstract no. 101]. J Clin Pharmacol 2005; 45(9): 1091 plus poster presented at the 34th Annual Meeting of the American College of Clinical Pharmacology; 2005 Sep 11–13; Rockville (MD)

25.

Braun M, Cawello W, Horstmann R. Lack of pharmacokinetic interaction between the dopamine agonist rotigotine and levodopa/carbidopa [abstract no. 4775 plus poster]. 16th International Congress on Parkinson’s Disease and Related Disorders; 2005 June 5–9; Berlin

26.

Watts RL, Wendt J, Nausieda PL, et al. Efficacy, safety, and tolerability of the rotigotine transdermal patch in patients with early-stage, idiopathic Parkinson’s disease: a multicenter, multinational, randomized, double-blind, placebo-controlled trial [abstract no. P737]. Mov Disord 2004 Jun 14; 19Suppl. 9: S258 plus poster presented at the 8th International Congress of Parkinson’s Disease and Movement Disorders; 2004 Jun 14–17; Rome

27.

Quinn N. for the SP 511 Investigators. Rotigotine transdermal delivery system (TDS) (SPM 962) — a multicenter, double-blind, randomized, placebo-controlled trial to asses the safety and efficacy of rotigotine TDS in patients with advanced Parkinson’s disease [abstract no. P-TU-223]. Parkinsonism Relat Disord 2001; 7Suppl. 1: S66 plus poster presented at the 14th International Congress on Parkinson’s Disease; 2001 Jul 27–Aug 1; Helsinki

28.

LeWitt PA, Chang F-L, Fazzini E, et al. Rotigotine transdermal system in treatment of patients with advanced-stage Parkinson’s disease [abstract no. SC115]. 9th Congress of the European Federation of Neurological Societies; 2005 Sep 17–20; Athens

29.

Babic T, Boroojerdi B, Randerath O, et al. Rotigotine CDS patch in advanced-stage, idiopathic Parkinson’s disease: a parallel group, open-label, dose-escalation trial [abstract no. P05.095]. Neurology 2004 Apr 13; 62(7 Suppl. 5): A399

Titel: Rotigotine
In Parkinson’s Disease
verfasst von: Neil A. Reynolds
Keri Wellington
Stephanie E. Easthope
Publikationsdatum: 01.11.2005
Verlag: Springer International Publishing
Erschienen in: CNS Drugs / Ausgabe 11/2005
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI: https://doi.org/10.2165/00023210-200519110-00006

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2005

Rotigotine

Advances in Drug Treatments for Children and Adolescents with Autism and Other Pervasive Developmental Disorders

The Role of Alpha-4 Integrin in the Aetiology of Multiple Sclerosis

The Use of Triptans in the Management of Menstrual Migraine

Rotigotine

Overtreatment in Epilepsy

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Akuter Schwindel: Wann lohnt sich eine MRT?

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Frühe Alzheimertherapie lohnt sich

Viel Bewegung in der Parkinsonforschung

Update Neurologie